NASDAQ
27.06.25 | 21:59
1,860 US-Dollar
-4,12 % -0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 17.06. | Milestone Pharmaceuticals resubmits Cardamyst filing after FDA response | 3 | Investing.com | ||
| 16.06. | Milestone Pharma Announces Submission Of Its Response To CRL Regarding NDA For CARDAMYST | 1 | RTTNews | ||
| 16.06. | Milestone Pharmaceuticals submits response to FDA for PSVT drug | 3 | Investing.com | ||
| 12.06. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Milestone Pharmaceuticals GAAP EPS of -$0.31 misses by $0.13 | 10 | Seeking Alpha | ||
| 14.05. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | 430 | GlobeNewswire (Europe) | Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 14.05. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.04. | TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty | 4 | Investing.com | ||
| 01.04. | Milestone Pharmaceuticals stock rating cut to hold by TD Cowen | 4 | Investing.com | ||
| 28.03. | Milestone Pharma says FDA declined to approve heart disorder therapy | 11 | Seeking Alpha | ||
| 28.03. | Milestone Pharma: FDA Issues CRL Regarding New Drug Application For CARDAMYST Nasal Spray | 5 | RTTNews | ||
| 28.03. | Milestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVT | 305 | GlobeNewswire (Europe) | CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025... ► Artikel lesen | |
| 28.03. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.03. | HotStocks USA: +11 % bei Milestone Pharmaceuticals | 3 | stock3.com | ||
| 13.03. | Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates | 5 | RTTNews | ||
| 13.03. | Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 13.03. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update | 216 | GlobeNewswire (Europe) | FDA PDUFA review goal date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025... ► Artikel lesen | |
| 13.03. | Milestone Pharmaceuticals Inc. - 10-K, Annual Report | 1 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,975 | +2,64 % | DZ BANK stuft BAYER AG auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Aktien von Bayer bei einem fairen Wert von 36 Euro auf "Kaufen" belassen. Der Agrarchemie- und Pharmakonzern sei besser als erwartet ins Jahr gestartet... ► Artikel lesen | |
| NOVO NORDISK | 58,70 | +0,09 % | JPMORGAN stuft NOVO NORDISK auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Novo Nordisk nach Studiendaten zu Cagrisema auf "Overweight" mit einem Kursziel von 650 dänischen Kronen belassen. Der Markt... ► Artikel lesen | |
| PFIZER | 20,665 | +0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
| GILEAD SCIENCES | 94,33 | -0,18 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
| MERCK & CO | 67,40 | -0,15 % | Merck & Co.: Patente, Prognosen und eine fatale Fehleinschätzung | Auslaufende Patente, geopolitische Risiken, Abschreibungen. Merck steht unter Druck, doch abseits der Schlagzeilen läuft das Geschäft erstaunlich gut Den vollständigen Artikel lesen ... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 378,70 | +0,49 % | Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug | ||
| EYEPOINT PHARMACEUTICALS | 8,400 | +1,89 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| BAUSCH HEALTH | 5,500 | -0,25 % | Bausch Health Companies Inc. - 8-K, Current Report | ||
| ROCKET LAB | 30,200 | -0,10 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 14,250 | -3,06 % | ASSEMBLY BIOSCIENCES, INC. - 8-K, Current Report | ||
| ASTRIA THERAPEUTICS | 4,720 | -0,84 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 7,360 | +0,41 % | Newron Pharmaceuticals - Next stage unlocked for evenamide | Newron has announced receipt of regulatory clearance to conduct its Phase III programme for evenamide (ENIGMA-TRS), taking it one step closer to the market. It will comprise two separate trials: ENIGMA-TRS... ► Artikel lesen | |
| OPKO HEALTH | 1,114 | -1,59 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| ALTIMMUNE | 2,951 | -0,87 % | Altimmune, Inc: Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH | First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 97,50 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen |
Das Unternehmen MILESTONE PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,860 Euro und damit -4,12 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MILESTONE PHARMACEUTICALS INC finden Sie auf Wallstreet Online.